Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Liver Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 37Nivolumab 21pembrolizumab 18Bevacizumab 12Cyclophosphamide 10durvalumab 9fludarabine 8atezolizumab 8Magnetic Resonance Spectroscopy 8lenvatinib 7Radiosurgery 7Ipilimumab 7Radiotherapy 6Irinotecan 6Oxaliplatin 5Leucovorin 5tremelimumab 4toripalimab 4tislelizumab 4sintilimab 4cabozantinib 4budigalimab 4Specimen Handling 4Sirolimus 4Interleukin-2 4Fluorouracil 4Doxorubicin 4Capecitabine 4130-nm albumin-bound paclitaxel 4spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Hepatocellular × BIIB022 × Clear all
NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Biogen

Phase 1 Completed
40 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡